Other substances

Aprepitant

A morpholine-based antiemetic.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

General information

Aprepitant on PubChem

Marketed as

APRECAP; APREPITANT; CINVANTI; EMEND

 

Structure image - Aprepitant

C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F

Supporting references

Link Tested on Impact factor Notes Publication date
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
3CLpro Small molecule In silico 		in silico 2.09

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Sep/17/2020

AI-suggested references

Link Publication date
Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation.
Mar/01/2022
Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an in silico perspective
Jul/13/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04470622 Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) Terminated Phase 2 Jul/20/2020 Jun/03/2021
  • Alternative id - HTX-019-202
  • Interventions - Drug: Aprepitant injectable emulsion|Drug: Saline Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Helen Keller Hospital, Sheffield, Alabama, United States|University of California, Irvine Medical Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 27
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of subjects alive and discharged from the hospital.|Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).|Time to discharge from hospital.|Change from Baseline in Interleukin 6 (IL-6).|Incidence of treatment-emergent adverse events.
Export (.csv)